Acute Disseminated Encephalomyelitis
Acute disseminated encephalomyelitis (ADEM) is an uncommon immune-mediated disorder that predominantly affects the central nervous system, particularly in pediatric populations. As an esteemed organization with a wealth of experience in therapeutic development for autoimmune diseases, we take great pride in offering tailored solutions for ADEM therapy development to pharmaceutical companies worldwide.
Introduction to Acute Disseminated Encephalomyelitis
Acute disseminated encephalomyelitis (ADEM) is an autoimmune disease characterized by inflammation and demyelination in the central nervous system. It often follows an infection or vaccination and can result in a wide range of neurological symptoms, including encephalopathy, seizures, motor deficits, and optic neuritis. ADEM is typically a monophasic illness, meaning it occurs as a single episode, but recurrent cases have been reported.
Research has shown the presence of perivenous demyelination in ADEM cases, which distinguishes it from other demyelinating diseases like multiple sclerosis (MS). Inflammatory cells, including macrophages, lymphocytes, and microglia, are also observed in the affected areas of the brain. Additionally, the presence of inflammatory markers, such as increased levels of interleukin-6 (IL-6) in the cerebrospinal fluid (CSF), suggests the involvement of immune dysregulation in ADEM.
Fig.1 Spectrum of acquired demyelinating syndromes. (Paolilo R. B., et al., 2020)
Therapy Discovery and Development for Acute Disseminated Encephalomyelitis
Due to the self-limiting nature of ADEM, therapeutic interventions are primarily aimed at managing symptoms and suppressing the inflammatory response. High-dose intravenous (IV) corticosteroids, such as IV methylprednisolone, are considered the first-line therapeutic for ADEM. These corticosteroids help reduce inflammation and promote recovery. In cases where patients do not respond to corticosteroids or have contraindications, intravenous immunoglobulin (IVIG) therapy can be considered as a second-line therapeutic. IVIG has immunomodulatory effects, potentially inhibiting the activation of myelin-reactive T cells and binding to pathogenic antibodies.
At our renowned organization, we stand as pioneers in delivering remarkable services dedicated to ADEM diagnostics and therapeutic development. If you are seeking to explore the vast array of therapeutic development options available, we extend a warm invitation to click on the link provided below.
Our Services
Our company offers comprehensive preclinical research services for ADEM that encompass a wide range of studies and evaluations. Our dedicated team of experts conducts in-depth investigations into the efficacy and safety of potential ADEM therapies using our established animal models and in vitro models. Through rigorous testing and analysis, we aim to provide valuable insights into the potential benefits and risks of new therapeutic approaches.
Experimental Autoimmune Encephalomyelitis (EAE) Modes
We develop immunization protocols utilizing relevant myelin protein products and adjuvants to induce the desired clinical and histological features of EAE. By carefully optimizing the model's induction parameters, we ensure its suitability for investigating pathogenesis and testing potential therapeutic approaches.
By utilizing specific cell types involved in ADEM, such as microglia, astrocytes, and oligodendrocytes, we can gain insights into the interplay between these cells and the immune system. Our company offers comprehensive cell-based model development services to support ADEM drug development.
By replicating the cellular composition and spatial organization of the brain, these organoids enable researchers to study the interactions between different cell types. Our company's expertise in brain organoid development ensures the generation of physiologically relevant models for ADEM research.
Through rigorous preclinical testing and optimization, we aim to identify safe and effective therapies. Beyond the aforementioned repertoire of services and models, our expertise extends to crafting personalized solutions and designing disease models that impeccably align with your unique needs. If our comprehensive range of offerings has piqued your interest, we wholeheartedly encourage you to connect with us without any hesitation.
References
- Paolilo R. B., et al. "Acute disseminated encephalomyelitis: current perspectives." Children 7.11 (2020): 210.
- Filippi M., et al. "Acute disseminated encephalomyelitis." White matter diseases: an update for neurologists (2020): 109-125.